Individualized Bayesian Risk Assessment for Cervical Squamous Neoplasia

Curry, 2018, Screening for cervical cancer: US preventive services task force recommendation statement, JAMA, 320, 674, 10.1001/jama.2018.10897 Noone, 2018 Kim, 2018, Screening for cervical cancer in primary care: A decision analysis for the us preventive services task force, JAMA, 320, 706, 10.1001/jama.2017.19872 Austin, 2010, The Pittsburgh cervical cancer screening model: A risk assessment tool, Arch Pathol Lab Med, 134, 744, 10.5858/134.5.744 Onisko, 2016, How to interpret the results of medical time series data analysis: Classical statistical approaches versus dynamic Bayesian network modeling, J Pathol Inform, 7, 50, 10.4103/2153-3539.197191 Austin, 2016, Increased cervical cancer risk associated with extended screening intervals after negative human papillomavirus test results: Bayesian risk estimates using the Pittsburgh cervical cancer screening model, J Am Soc Cytopathol, 5, 9, 10.1016/j.jasc.2015.05.001 Onisko, 2019, Application of Bayesian network modeling to pathology informatics, Diagn Cytopathol, 47, 41, 10.1002/dc.23993 Lee, 1997, Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening, Obstet Gynecol, 90, 278, 10.1016/S0029-7844(97)00228-7 Terry, 2001, Detection of highrisk HPV types by the hybrid capture 2 test, J Med Virol, 65, 155, 10.1002/jmv.2015 Einstein, 2010, Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology, Gynecol Oncol, 118, 116, 10.1016/j.ygyno.2010.04.013 Iftner, 2015, Head-to-head comparison of the rna-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany, J Clin Microbiol, 53, 2509, 10.1128/JCM.01013-15 Solomon, 2002, The 2001 Bethesda system: Terminology for reporting results of cervical cytology, JAMA, 287, 2114, 10.1001/jama.287.16.2114 Davey, 2007, Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study, BMJ, 335, 31, 10.1136/bmj.39219.645475.55 2016, Committee on Practice Bulletins—Gynecology. Practice bulletin no. 168: Cervical cancer screening and prevention, Obstet Gynecol, 128, e111 Saslow, 2012, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer, CA Cancer J Clin, 62, 147, 10.3322/caac.21139 Massad, 2013, 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors, J Low Genit Tract Dis, 17, S1, 10.1097/LGT.0b013e318287d329 Castle, 2010, The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer, Obstet Gynecol, 116, 76, 10.1097/AOG.0b013e3181e3e719 Demarco, 2017, Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: The foundation of risk-based cervical screening guidelines, J Low Genit Tract Dis, 21, 261, 10.1097/LGT.0000000000000343 Katki, 2013, Five-year risks of CIN 3 + and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results, J Low Genit Tract Dis, 17, S50, 10.1097/LGT.0b013e3182854282 Schiffman, 2018, Relative performance of HPV and cytology components of cotesting in cervical screening, J Natl Cancer Inst, 110, 501, 10.1093/jnci/djx225 US Department of Health and Human Services, Food and Drug Administration, 2011 Miller, 2003, Screening interval and risk of invasive squamous cell cervical cancer, Obstet Gynecol, 101, 29, 10.1097/00006250-200305000-00043 Strander, 2007, Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: Population based cohort study, BMJ, 335, 10.1136/bmj.39363.471806.BE Adegoke, 2012, Cervical cancer trends in the United States: A 35-year population-based analysis, J Womens Health (Larchmt), 21, 1031, 10.1089/jwh.2011.3385 Gunnell, 2007, A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: Evidence of effectiveness and overtreatment, Cancer Epidemiol Biomarkers Prev, 16, 2641, 10.1158/1055-9965.EPI-07-0278 Kinney, 2003, Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening, Acta Cytol, 47, 167, 10.1159/000326498 Vizcaino, 1998, International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas, Int J Cancer, 75, 536, 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.0.CO;2-U Sasieni, 2009, Screening and adenocarcinoma of the cervix, Int J Cancer, 125, 525, 10.1002/ijc.24410 Lew, 2017, Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: Effectiveness and economic assessment for the National Cervical Screening Program, Lancet Public Health, 2, e96, 10.1016/S2468-2667(17)30007-5 Hakama, 2014, Sensitivity effect and overdiagnosis in screening for cancers with detectible preinvasive phase, Int J cancer, 136, 928, 10.1002/ijc.29053 Malila, 2013, The HPV test has similar sensitivity but more overdiagnosis than the Pap test: A randomised health services study on cervical cancer screening in Finland, Int J Cancer, 132, 2141, 10.1002/ijc.27850